GlassScriptPhysician profile
Jennifer J Lansman
NPI 1659027993
$4,366.72
in general payments reported to CMS, 2019-2025
24 companies · none reported in 2025
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2022: $1,383 · 2023: $2,377 · 2024: $607.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,790 · Education: $193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,790.09 |
| Education | $193.33 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Regeneron Healthcare Solutions, INC. | $732.75 | 2022-2024 | Dupixent |
| Abbvie INC. | $643.79 | 2022-2024 | |
| Sun Pharmaceutical Industries INC. | $459.42 | 2022-2024 | Ilumya, Absorica Ld, Winlevi |
| Lilly USA, LLC | $402.20 | 2022-2024 | Olumiant, Taltz |
| Genzyme Corporation | $358.26 | 2022-2024 | |
| Incyte Corporation | $319.60 | 2022-2024 | Opzelura |
| Novartis Pharmaceuticals Corporation | $273.57 | 2022-2024 | |
| Amgen INC. | $212.41 | 2022-2023 | Otezla, Enbrel |
| Ortho Dermatologics, A Division of Bausch Health US, LLC | $160.65 | 2022-2024 | Jublia, Arazlo, Duobrii |
| Janssen Biotech, INC. | $153.61 | 2022-2024 | Tremfya |
| E.R. Squibb & Sons, L.L.C. | $132.33 | 2023 | Sotyktu |
| Almirall LLC | $103.34 | 2022-2024 | Seysara |
| Kerecis Limited | $99.32 | 2023-2024 | Kerecis Omega3 Marigen, Kerecis Omega3 Surgiclose, Kerecis Omega3 Graftguide |
| Pfizer INC. | $44.70 | 2023-2024 | |
| Arcutis Biotherapeutics, INC. | $40.23 | 2023 |
Show all 24 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Leo Pharma INC. | $39.84 | 2022 | |
| Nabriva Therapeutics, Plc | $33.79 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $30.81 | 2022-2024 | Spevigo |
| Dermavant Sciences, INC. | $30.14 | 2023 | Vtama |
| Ucb, INC. | $23.96 | 2023 | Bimzelx |
| Blueprint Medicines Corporation | $22.07 | 2023 | |
| Mayne Pharma Commercial LLC | $20.40 | 2022 | |
| Galderma Laboratories, L.P. | $15.50 | 2022 | |
| Kyowa Kirin, INC. | $14.03 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jennifer Lansman listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.